BIRC5 and cancer: The breast cancer dataset demonstrated that BIRC5 expression was significantly associated with adverse OS rates (BIRC5 probe ILMN_1803124: HR = 5.49, 95% CI: 2.32–12.97, P < 0.001; BIRC5 probe ILMN_2349459: HR = 1.85, 95% CI: 1.27–2.6, P = 0.0014), while the Kaplan-Meier analysis of the four cancer types revealed that low BIRC5 expression was significantly associated with better overall survival for breast-, lung and gastric cancer (Fig. 5).